- Home
- PRQR vs VRCA Comparison
PRQR vs VRCA Comparison
Compare PRQR & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- VRCA
- Stock Information
- Founded
- PRQR 2012
- VRCA 2013
- Country
- PRQR Netherlands
- VRCA United States
- Employees
- PRQR N/A
- VRCA N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- VRCA Health Care
- Exchange
- PRQR Nasdaq
- VRCA Nasdaq
- Market Cap
- PRQR 309.5M
- VRCA 363.1M
- IPO Year
- PRQR 2014
- VRCA 2018
- Fundamental
- Price
- PRQR $3.62
- VRCA $0.99
- Analyst Decision
- PRQR Strong Buy
- VRCA Buy
- Analyst Count
- PRQR 4
- VRCA 6
- Target Price
- PRQR $7.13
- VRCA $7.33
- AVG Volume (30 Days)
- PRQR 635.3K
- VRCA 907.0K
- Earning Date
- PRQR 11-07-2024
- VRCA 11-04-2024
- Dividend Yield
- PRQR N/A
- VRCA N/A
- EPS Growth
- PRQR N/A
- VRCA N/A
- EPS
- PRQR N/A
- VRCA N/A
- Revenue
- PRQR $20,506,357.00
- VRCA $9,210,000.00
- Revenue This Year
- PRQR $298.83
- VRCA $123.42
- Revenue Next Year
- PRQR N/A
- VRCA $124.76
- P/E Ratio
- PRQR N/A
- VRCA N/A
- Revenue Growth
- PRQR 306.68
- VRCA 187.45
- 52 Week Low
- PRQR $1.18
- VRCA $0.70
- 52 Week High
- PRQR $4.62
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- PRQR 54.60
- VRCA 42.73
- Support Level
- PRQR $3.57
- VRCA $0.80
- Resistance Level
- PRQR $3.70
- VRCA $1.09
- Average True Range (ATR)
- PRQR 0.22
- VRCA 0.12
- MACD
- PRQR -0.08
- VRCA 0.03
- Stochastic Oscillator
- PRQR 18.06
- VRCA 75.26
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.